Zentalis Pharmaceuticals, Inc.
ZNTL
$3.87
-$0.16-3.97%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -57.35% | 26.78% | 25.82% | 33.54% | 69.56% |
| Total Depreciation and Amortization | -4.38% | -42.37% | -50.47% | -50.16% | -51.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 847.90% | -78.18% | -62.17% | -75.80% | -99.15% |
| Change in Net Operating Assets | 120.79% | -141.51% | 80.53% | 83.88% | -162.49% |
| Cash from Operations | -7.28% | -0.98% | 22.07% | 38.78% | 1.23% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 767.69% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.70% | -25.75% | 0.11% | -41.30% | -13.85% |
| Cash from Investing | -1.17% | -25.85% | 0.51% | -41.30% | -11.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 75.13% | -- | 25.00% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -694.18% | -- | 25.00% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -65.06% | -150.64% | 58.53% | -65.66% | -576.56% |